Related Experiment Video
Updated: Jun 2, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
HLA class I and advanced melanoma in Israeli Jews
J Schachter1, T Klein, B Klein
1RABIN MED CTR,TISSUE TYPING LAB,IL-49100 PETAH TIQWA,ISRAEL. RABIN MED CTR,ONCOL UNIT,IL-49100 PETAH TIQWA,ISRAEL. TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL.
Abstract:
KLA class I antigen was studied in Jewish melanoma patients. The frequency of HLA A24, A26 and B38 was significantly higher in the melanoma patients (34.7%, 39.1% and 38.6%, respectively) compared to controls (16.6%, 18.5% and 20.6%, respectively) (p<0.005). HLA A24 antigen was significantly higher in the metastatic patients (44.8%) compared to the non-metastatic (11.1%) (p<0.001). The frequency of this antigen was also higher in the patients with recurrent disease (16.6%) than in the high risk patients with no recurrence (11.1%). HLA class I and A24 may play a role in the biologic behavior of malignant melanoma.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Non-LTR Retrotransposons

